

IN THE CLAIMS:

Please cancel claims 1-13, without prejudice, and add the following new claims:

Sub
14 --14. A method of preventing or controlling cataract or ^{*after cataract formation*} ~~cataract-like disorders~~ in the eye of a mammalian subject which comprises the step of administering to the subject an effective amount of one or more inhibitors of TGF β .--

D --15. The method according to claim 14 wherein the one or more inhibitors of TGF β are selected from proteins, ^{*glycoproteins*} ~~glycoproteins~~ and proteoglycans.--

A --16. The method according to claim 15 wherein the protein inhibitors of TGF β are selected from antibodies and peptide growth factors.--

--17. The method according to claim 15 wherein the glycoprotein inhibitors of TGF β are selected from α_2 -macroglobulin, laminin and collagen.--

--18. The method according to claim 15 wherein the proteoglycan inhibitors of TGF β are selected from decorin, heparan sulfate proteoglycans and biglycan.--

--19. An ophthalmological formulation comprising one or more inhibitors of TGF β in an ophthalmologically acceptable carrier but excluding conventional pharmaceutically acceptable carriers.--

--20. The ophthalmological formulation according to claim 19 wherein the one or more inhibitors of TGF β are selected from proteins, glycoproteins and proteoglycans.--

--21. The ophthalmological formulation according to claim 20 wherein the protein inhibitors of TGF β are selected from antibodies and peptide growth factors.--

--22. The ophthalmological formulation according to claim 20 wherein the glycoprotein inhibitors of TGF β are selected from α_2 -macroglobulin, laminin and collagen.--

--23. The ophthalmological formulation according to claim 20 wherein the proteoglycan inhibitors of TGF β are selected from decorin, heparan sulfate proteoglycans and biglycan.--

*Sub
GB*
--24. A method of preventing or controlling aftercataract formation in the eye of a mammalian subject following lens implant surgery which comprises the step of implanting in the eye of the subject a lens coated with one or more TGF β inhibitors.--

--25. The method according to claim 24 wherein the one or more inhibitors of TGF β are selected from proteins, glycoproteins and proteoglycans.--

--26. The method according to claim 25 wherein the protein inhibitors of TGF β are selected from antibodies and peptide growth factors.--

--27. The method according to claim 25 wherein the glycoprotein inhibitors of TGF β are selected from α_2 -macroglobulin, laminin and collagen.--

--28. The method according to claim 25 wherein the proteoglycan inhibitors of TGF β are selected from decorin, heparan sulfate proteoglycans and biglycan.--

--29. A lens implant comprising a coating, the coating including one or more TGF β inhibitors.--

--30. The lens implant according to claim 29 coated with one or more TGF β inhibitors selected from proteins, glycoproteins and proteoglycans.--

--31. The lens implant according to claim 30 wherein the protein inhibitors of TGF β are selected from antibodies and peptide growth factors.--

--32. The lens implant according to claim 30 wherein the glycoprotein inhibitors of TGF β are selected from α_2 -macroglobulin, laminin and collagen.--

--33. The lens implant according to claim 30 wherein the proteoglycan inhibitors of TGF β are selected from decorin, heparan sulfate proteoglycans and biglycan.--

--34. The use of inhibitors of TGF β in the manufacture ^{of an} ~~and~~ ophthalmological formulation for preventing or controlling cataract or cataract-like disorders.--